January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

Called the Primary Prevention Trial, the new study investigates whether remternetug - an investigational antibody being developed by ... an FDA-approved Alzheimer's therapy also produced by Lilly.

A US university has launched a prevention trial examining the use of Eli Lilly’s investigational ... determine if the investigational monoclonal antibody remternetug can remove plaques of ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

Daiichi Sankyo is spending $132.5 million to buy an antibody ... Sankyo in cancer therapy. Samsung Biologics disclosed a contract manufacturing deal with an EU-based pharmaceutical company. Mediar ...

In the last 5 years significant progress has been made in potential dementia treatments, yet many of these treatments come ...

Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for slowing its progression. T ...

Eli Lilly and RNAi therapeutics specialist OliX Pharmaceuticals have entered into a global licensing agreement to advance a ...

AnaptysBio (ANAB) stock climbs as its antibody therapy rosnilimab meets key goals in mid-stage rheumatoid arthritis trial, ...